Compare ADT Inc (ADT) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADT Inc vs Neurocrine Biosciences Inc — how do they compare? ADT Inc trades at $7.45 (market cap $5.44B), while Neurocrine Biosciences Inc trades at $152.18 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is far larger — about 3× ADT Inc's market cap, and ADT Inc pays a 2.95% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| ADT | NBIX | |
|---|---|---|
Market Cap | $5.44B | $16.46B |
Sector | Industrials | Health |
52-Week High | $8.85 | $185.50 |
52-Week Low | $6.30 | $123.10 |
Enterprise Value | $13.13B | $16.48B |
Dividend Yield | 2.95% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADT Inc
ADT Inc is a provider of monitored security, interactive home and business automation, and related monitoring services in the United States and Canada. ADT offers residential, commercial, and multi-site customers a comprehensive set of burglary, video, access control, fire and smoke alarm, and medical alert solutions. It provides interactive home and business automation solutions designed to control access, react to movement, and sense carbon monoxide, flooding, changes in temperature or other environmental conditions, as well as address personal emergencies, such as injuries and medical emergencies. In addition, it offers professional monitoring of third-party devices through ADT Canopy platform. The product brands of the company are ADT and ADT Pulse, and Protection One brand.
Read more on ADT →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
